• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原卟啉病患者红细胞和血浆原卟啉水平的纵向分析

Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria.

作者信息

Gou Eric, Weng Cindy, Greene Tom, Anderson Karl E, Phillips John D

机构信息

University of Texas Medical Branch, Galveston, TX.

University of Utah, Salt Lake City, UT.

出版信息

J Appl Lab Med. 2018 Sep 1;3(2):213-221. doi: 10.1373/jalm.2017.025874.

DOI:10.1373/jalm.2017.025874
PMID:33636932
Abstract

BACKGROUND

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are inherited cutaneous porphyrias resulting from decreased activity of ferrochelatase and gain-of-function mutations of δ-aminolevulinic acid synthase-2, respectively. Both of these protoporphyrias cause increased protoporphyrin levels that cause photosensitivity and may lead to hepatopathy and further increases in erythrocyte and plasma porphyrin levels.

METHODS

We evaluated erythrocyte protoporphyrin and plasma porphyrin levels in all subjects with EPP (83 subjects) or XLP (9 subjects) without evidence of liver disease tested repeatedly at a single laboratory over 25 years.

RESULTS

Intersubject variation contributed more than intrasubject variation (78.86% vs 21.14%) to overall variability, and longitudinal variability, estimated by CV, averaged 26%. Erythrocyte total protoporphyrin levels were similar in males and females with EPP (ratio, 0.99; 95% CI, 0.82-1.21; P = 0.96) but were higher in males than females with XLP, although this difference was not statistically significant (ratio, 0.76; 95% CI, 0.43-1.36; P = 0.35). Analysis of 20 subjects from 9 separate families showed significant effects of family compared with effects of individual variation on total variance (50% vs 25%; P < 0.0001).

CONCLUSION

Variation of erythrocyte total protoporphyrin up to 25% is expected in patients with protoporphyria, whereas greater increases might raise concern for protoporphyric hepatopathy.

摘要

背景

红细胞生成性原卟啉病(EPP)和X连锁原卟啉病(XLP)是遗传性皮肤卟啉病,分别由亚铁螯合酶活性降低和δ-氨基乙酰丙酸合酶-2功能获得性突变引起。这两种原卟啉病都会导致原卟啉水平升高,从而引起光敏感,并可能导致肝病以及红细胞和血浆卟啉水平进一步升高。

方法

我们评估了25年间在单个实验室反复检测的所有无肝病证据的EPP患者(83例)或XLP患者(9例)的红细胞原卟啉和血浆卟啉水平。

结果

受试者间变异对总体变异性的贡献大于受试者内变异(78.86%对21.14%),通过CV估计的纵向变异性平均为26%。EPP男性和女性的红细胞总原卟啉水平相似(比值为0.99;95%CI为0.82-1.21;P = 0.96),但XLP男性高于女性,尽管这种差异无统计学意义(比值为0.76;95%CI为0.43-1.36;P = 0.35)。对来自9个不同家庭的20名受试者的分析显示,与个体变异对总方差的影响相比,家庭影响显著(50%对25%;P < 0.0001)。

结论

原卟啉病患者的红细胞总原卟啉预计会有高达25%的变异,而更大幅度的升高可能提示原卟啉性肝病。

相似文献

1
Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria.原卟啉病患者红细胞和血浆原卟啉水平的纵向分析
J Appl Lab Med. 2018 Sep 1;3(2):213-221. doi: 10.1373/jalm.2017.025874.
2
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.北美患者的失活型亚铁螯合酶和活性型红系特异性 5-氨基酮戊酸合酶突变导致的红细胞生成性原卟啉症和 X 连锁原卟啉症揭示了新的突变和 X 连锁原卟啉症的高发率。
Mol Med. 2013 Apr 30;19(1):26-35. doi: 10.2119/molmed.2012.00340.
3
Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.先天性红细胞生成性卟啉病和红细胞生成性原卟啉病:尿卟啉原 III 合酶和 20 个亚铁螯合酶新突变的鉴定。
Mol Genet Metab. 2019 Nov;128(3):358-362. doi: 10.1016/j.ymgme.2018.08.015. Epub 2018 Aug 31.
4
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.北美红细胞生成性原卟啉症和X连锁原卟啉症患者的临床、生化及遗传学特征
JAMA Dermatol. 2017 Aug 1;153(8):789-796. doi: 10.1001/jamadermatol.2017.1557.
5
A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria.口服铁剂治疗红细胞生成性原卟啉病和X连锁原卟啉病的初步研究。
Mol Genet Metab Rep. 2022 Nov 14;33:100939. doi: 10.1016/j.ymgmr.2022.100939. eCollection 2022 Dec.
6
Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.红细胞生成性和X连锁原卟啉症的已知及新出现特征
Diagnostics (Basel). 2022 Jan 8;12(1):151. doi: 10.3390/diagnostics12010151.
7
Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrias.红细胞原卟啉测定在卟啉病诊断和监测中的陷阱。
Clin Chem. 2015 Dec;61(12):1453-6. doi: 10.1373/clinchem.2015.245456. Epub 2015 Oct 19.
8
Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.红细胞生成性原卟啉症和 X 连锁原卟啉症:病理生理学、遗传学、临床表现和治疗。
Mol Genet Metab. 2019 Nov;128(3):298-303. doi: 10.1016/j.ymgme.2019.01.020. Epub 2019 Jan 24.
9
Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.超越色素沉着:瑞士红细胞生成性原卟啉症患者接受阿法美拉肽治疗期间肝脏保护的迹象,一项观察性研究。
Ther Adv Rare Dis. 2021 Dec 21;2:26330040211065453. doi: 10.1177/26330040211065453. eCollection 2021 Jan-Dec.
10
Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro.红细胞生成性原卟啉病与铅中毒:皮肤光敏性差异的分子基础。I. 体内和体外红细胞中原卟啉消失速率的差异
J Clin Invest. 1975 Dec;56(6):1519-27. doi: 10.1172/JCI108233.

引用本文的文献

1
Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.阿法美拉肽治疗原卟啉病:对美国一组患者生活质量和实验室参数的影响
Life (Basel). 2024 May 28;14(6):689. doi: 10.3390/life14060689.
2
How I treat erythropoietic protoporphyria and X-linked protoporphyria.我是如何治疗红细胞生成性原卟啉症和 X 连锁原卟啉症的。
Blood. 2023 Jun 15;141(24):2921-2931. doi: 10.1182/blood.2022018688.
3
A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria.
口服铁剂治疗红细胞生成性原卟啉病和X连锁原卟啉病的初步研究。
Mol Genet Metab Rep. 2022 Nov 14;33:100939. doi: 10.1016/j.ymgmr.2022.100939. eCollection 2022 Dec.
4
ABCB6 polymorphisms are not overly represented in patients with porphyria.ABCB6 多态性在卟啉症患者中并不过度表达。
Blood Adv. 2022 Feb 8;6(3):760-766. doi: 10.1182/bloodadvances.2021005484.
5
Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.一项伊曲康唑治疗红细胞生成性原卟啉症患者的初步研究结果。
Mol Genet Metab. 2019 Nov;128(3):309-313. doi: 10.1016/j.ymgme.2019.07.017. Epub 2019 Jul 31.